PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer

作者：Paula Ghaneh, Robert N. Hanson, Andrew Titman, Gill Lancaster, Catrin Plumpton, Huw Lloyd‐Williams, Seow Tien Yeo, Rhiannon Tudor Edwards, Colin Johnson, Mohammad Abu Hilal, Antony Higginson, Tom Armstrong, Andrew Malvern Smith, Andrew Frederick Scarsbrook, Colin J. McKay, Ross Carter, Robert Peter Sutcliffe, Simon R. Bramhall, Hemant Mahendrakumar Kocher, David Cunningham, Stephen P. Pereira, Brian Ritchie Davidson, David Wen-Wei Chang, Saboor Khan, Ian A. Zealley, Debashis Sarker, Bilal Al Sarireh, Richard Charnley, Dileep N. Lobo, Marianne C. Nicolson, Christopher Michael Halloran, Michael G.T. Raraty, Robert Sutton, Sobhan Vinjamuri, Jonathan Evans, Fiona Campbell, Jonathan J Deeks, Bal Sanghera, Wai‐Lup Wong, John P. Neoptolemos · 发表于：Health Technology Assessment · 年份：2018 · DOI：10.3310/hta22070 · 被引用次数：139 · 研究领域：Pancreatic and Hepatic Oncology Research、Medical Imaging Techniques and Applications、Pancreatitis Pathology and Treatment

Background Pancreatic cancer diagnosis and staging can be difficult in 10–20% of patients. Positron emission tomography (PET)/computed tomography (CT) adds precise anatomical localisation to functional data. The use of PET/CT may add further value to the diagnosis and staging of pancreatic cancer. Objective To determine the incremental diagnostic accuracy and impact of PET/CT in addition to standard diagnostic work-up in patients with suspected pancreatic cancer. Design A multicentre prospective diagnostic accuracy and clinical value study of PET/CT in suspected pancreatic malignancy. Participants Patients with suspected pancreatic malignancy. Interventions All patients to undergo PET/CT following standard diagnostic work-up. Main outcome measures The primary outcome was the incremental diagnostic value of PET/CT in addition to standard diagnostic work-up with multidetector computed tomography (MDCT). Secondary outcomes were (1) changes in patients’ diagnosis, staging and management as a result of PET/CT; (2) changes in the costs and effectiveness of patient management as a result of PET/CT; (3) the incremental diagnostic value of PET/CT in chronic pancreatitis; (4) the identification of groups of patients who would benefit most from PET/CT; and (5) the incremental diagnostic value of PET/CT in other pancreatic tumours. Results Between 2011 and 2013, 589 patients with suspected pancreatic cancer underwent MDCT and PET/CT, with 550 patients having complete data and in-range PE...